Connected Thinking

Leading Voices

Latest News

Selinexor Combo Effective For Relapsed Multiple Myeloma; Could it Benefit COVID Patients, Too?

Most multiple myeloma patients eventually relapse and their cancers become unresponsive to therapy, leaving them with limited remaining options and a poor prognosis. For these patients, the combination of selinexor plus dexamethasone represents a "critical new direction" in treatment.

Learn More

In Head-to-Head Matchup with KRd, VRd Remains Gold Standard of Care in Multiple Myeloma

The three-drug combination of bortezomib, lenalidomide, and dexamethasone (VRd) has been the standard therapy for patients with newly diagnosed multiple myeloma. The ENDURANCE trial presented at ASCO was a head-to-head effort to determine whether adding the next-generation proteasome inhibitor on the block, carfilzomib, to lenalidomide and dexamethasone (KRd) might perform even better. In short, it didn't.

Learn More

Brentuximab Vedotin is ‘Great Stride’ Toward Improving Lymphoma Outcomes

Brentuximab vedotin has added considerably to the lymphoma treatment options available to oncologists. The drug was initially approved for the treatment of relapsed Hodgkin's lymphoma following a stem cell transplant or, in patients who could not have a transplant, for those who had already undergone two or more chemotherapy treatments.

Learn More

Overcoming Racial Disparities in Multiple Myeloma Research and Care

Multiple myeloma has one of the most dramatic racial disparities of any cancers. Black Americans are more than twice as likely to get this cancer than white Americans. They're also more likely to die from multiple myeloma.

Learn More

Addressing Work-Life Balance Essential for Doctors’ Mental Health

More than half of physicians surveyed say they've struggled to maintain a healthy work-life balance, and the COVID-19 pandemic has only exacerbated the problem.

Learn More

Patients Need Careful Monitoring for CAR T-Cell Therapy Side Effects

Chimeric antigen receptor (CAR) T-cell therapy has become a major ally in the treatment of certain lymphomas and leukemias. However, this therapy is not without risks.

Learn More

PARP Inhibitors Boost Survival in Ovarian Cancer, Prompting New ASCO Guidelines on Their Use

PARP inhibitors are a class of drugs that inhibit one of the backup systems of DNA damage repair. Ovarian cancers with BRCA1, BRCA2, or certain other mutations have a defect in a major DNA damage repair pathway and are highly dependent on secondary pathways for their survival.

Learn More

The Promise of CAR T-Cell Therapy for Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, with response rates in studies of 85% or more, and about half of patients going into complete remission for a year or longer.

Learn More

Bispecific Antibodies Offer Lymphoma Patients a Promising New Therapeutic Option

Bispecific antibodies have exciting potential as a cancer therapy, due to their ability to simultaneously bind to two targets. Right now, this treatment is only available in investigational trials, but it has shown promising outcomes for patients with relapsed-refractory lymphoma who have already undergone a transplant, CAR T-cell therapy, or other lines of treatment.

Learn More

How to Prevent COVID-19 From Taking a Toll on Your Mental Health

We often talk about COVID-19 in terms of infections and deaths. What sometimes remains unspoken is the emotional toll this virus has had, not only on patients, but also on the doctors, nurses, and other health professionals who care for them. Research finds that these frontline medical workers face high levels of depression, anxiety, and stress.

Learn More

COVID-19 Has Shifted Much of Ovarian Cancer Care to Telemedicine

COVID-19 has shifted much of oncology practice from the medical office to the computer screen. Fear of infection in an already vulnerable population has led to the rapid expansion of remote care delivery. When ovarian cancer visits are done remotely, do patients lose out?

Learn More

Obinutuzumab Plus Venetoclax Produces Significant Survival Benefits in CLL

For decades, chemotherapy was the foundation of treatment for chronic lymphocytic leukemia (CLL). Today, monoclonal antibodies like obinutuzumab have become part of the standard of care for CLL patients.

Learn More

CAR T-Cell Therapy Produces ‘Remarkable’ Results in Multiple Myeloma, but It’s Still Not a Cure

Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, as evidenced by a trio of investigational therapies presented at this year's ASCO conference. 

Learn More

Nurturing the Relationship with Your Patients to Deliver Better Care

The strength of your relationship with your patients can have a significant impact on the quality of care you provide. Trust is one of the cornerstones of this relationship, but building that trust takes time and effort. And when you're juggling a heavy patient load, time can be a commodity in short supply.

Learn More

Delaying Treatment to Protect Ovarian Cancer Patients from COVID Has Benefits and Risks

Determining the most appropriate cancer treatment for your patients usually involves finding a delicate balance between the risks and benefits. How effective will the treatment be? Can a patient tolerate it? COVID adds one more factor into the equation.

Learn More

Could Ibrutinib Combined With Other Targeted Therapies and Chemo Be ‘the Future’ of B-Cell Lymphoma Treatment?

New research is enhancing our understanding of ibrutinib -- a Bruton's tyrosine kinase (BTK) inhibitor used to treat several different types of lymphoma, including chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and mantle cell lymphoma. It has also produced positive responses in B-cell lymphoma, but is so far only used in patients with relapsed/refractory disease.

Learn More

Cytokine Release Syndrome: The Downside of CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy has had great success thus far, producing lasting responses and even remissions in patients with relapsed or refractory hematologic cancers such as B-cell lymphoma and acute lymphoblastic leukemia (ALL).

Learn More

Improving Diversity in the Medical Community Key to Increasing Trust Among Black Patients

Having a doctor with the same racial background builds trust, and makes patients more likely to comply with medical advice, follow through with recommended screenings, and take their prescribed medications.

Learn More

CAR T-Cell Therapy is a ‘Revolution in Cancer Immunotherapy’

Chimeric antigen receptor (CAR) T-cell therapy is "paradigm changing" -- a "revolution in cancer immunotherapy." This treatment has ushered in a new era of therapy for blood cancer patients.

Learn More

What COVID-19 May Have Changed Forever About Multiple Myeloma Care — Telemedicine

COVID made oncologists rethink how to deliver care to their multiple myeloma patients, who are already at higher risk for infection. Providers increasingly shifted to telemedicine, and quickly realized its long-term benefits -- particularly for patients living far from major cancer centers.

Learn More

To Treat Ovarian Cancer With PARP Inhibitors or Not: Factoring the Progression-Free Survival Benefit and Side Effects Into the Decision

PARP inhibitors like niraparib (Zejula) are an effective tool against ovarian cancer. The NOVA trial established that niraparib as maintenance therapy in platinum-sensitive patients significantly improved progression-free survival compared to placebo, regardless of women's BRCA or homologous recombination deficiency (HRD) status. Then, the PRIMA study found the treatment extended PFS in patients with newly diagnosed ovarian cancer, with or without HRD deficiency.

Learn More

Cancer Affects Communities of Color Differently; How Providing Information on Prevention Can Help Level the Playing Field

Myeloma is just one example of a cancer that disproportionately impacts communities of color. Black Americans are twice as likely to have the precursor condition, monoclonal gammopathy of undetermined significance (MGUS) than are white Americans.

Learn More

Practical Advice for Physicians Struggling with Mental Illness

A mental health crisis is going on right now, and acknowledging it is a first step in addressing the problem. The demanding pace of the industry puts physicians at high risk for burnout, particularly in the midst of the high-stress environment that a global pandemic brings.

Learn More

‘Exciting’ New Therapies, Including BTK Inhibitors and Monoclonal Antibodies, Promising for CLL

In recent years, the treatment of chronic lymphocytic leukemia (CLL) has undergone a seismic shift, with chemotherapy being replaced by a new and more effective generation of drugs. One of the "really exciting" therapies to emerge is the Bruton's tyrosine kinase inhibitors.

Learn More

The Clinical Trial Disparity: Why So Few Black Patients Enroll

In trials for 24 of the 31 cancer drugs approved since 2015, fewer than 5% of participants were Black. As a result of this disparity, Black patients aren't getting access to experimental, and possibly lifesaving new therapies.

Learn More

COVID-19 Pandemic Reinforces the Need to Care for Your Mental Health

Fear of being perceived as weak or unable to do their jobs has created a stigma that prevents many physicians from accessing the mental health care they need. Inadequate treatment may be one reason why the risk for suicide is so much higher among doctors than it is in the general population.

Learn More

CAR T-Cell Therapy is ‘Exciting,’ But Also ‘Overwhelming’ for Patients

Chimeric antigen receptor (CAR) T-cell therapy has been transformative in blood cancer therapy, particularly for patients with previously poor outcomes; however, producing the CAR T cells can be a complex process.

Learn More

How to Bridge the Information Gap and Overcome Distrust When Treating Women of Color

People of color face the highest rates of cancer, and of cancer mortality, than any other racial or ethnic group. Black women in particular have higher death rates, despite having a lower incidence of cancer overall.

Learn More